---
id: 243
title: Staphylococcus aureus
category: organisms
subcategory: gram_positive_cocci
tags: [MRSA, MSSA, nafcillin, vancomycin, endocarditis, osteomyelitis, toxin]
difficulty: high
---

## Question

What are key clinical syndromes and treatment considerations for *S. aureus*? Use **"MSSA: Nafcillin/Cefazolin, MRSA: Vancomycin, Toxin Syndromes (TSS, SSSS), High Virulence"** framework.

## Answer

### **Key Clinical Syndromes:**

**Skin/Soft Tissue:**
- **Abscesses, furuncles, carbuncles** (most common)
- **Cellulitis, impetigo**
- **Necrotizing fasciitis** (rare)

**Bacteremia/Endocarditis:**
- **High-grade bacteremia** (often complicated)
- **Native valve endocarditis** (acute, destructive)
- **Prosthetic valve endocarditis**
- **Must search for source** (echo, remove infected devices)

**Bone/Joint:**
- **Osteomyelitis** (hematogenous, contiguous)
- **Septic arthritis** (most common cause)
- **Prosthetic joint infection**
- **Vertebral osteomyelitis** (IVDU, bacteremia)

**Pneumonia:**
- **Community-acquired** (post-influenza, necrotizing)
- **Healthcare-associated** (VAP, post-surgical)
- **Lung abscess, empyema**

**Device-Related:**
- **CRBSI** (central line bloodstream infection)
- **Prosthetic device infections** (pacemaker, joint, vascular graft)

**Toxin-Mediated:**
- **Toxic shock syndrome (TSS):** TSST-1, superantigen
- **Staphylococcal scalded skin syndrome (SSSS):** Exfoliative toxins
- **Food poisoning:** Preformed enterotoxin (rapid onset, 1-6h)

### **MRSA vs MSSA:**

**MRSA (Methicillin-Resistant *S. aureus*):**
- **mecA gene** (altered PBP2a) → resistance to all β-lactams
- **Community-associated MRSA (CA-MRSA):** USA300 clone, PVL toxin (necrotizing)
- **Healthcare-associated MRSA (HA-MRSA):** USA100, USA200

**MSSA (Methicillin-Susceptible *S. aureus*):**
- **Susceptible to nafcillin, cefazolin**

### **Treatment:**

**MSSA Infections:**

**Bacteremia/Endocarditis:**
- **Nafcillin 2g IV q4h** OR **cefazolin 2g IV q8h × 4-6 weeks**
- **Nafcillin preferred** (better CNS penetration)
- **Do NOT use vancomycin** (inferior outcomes vs. nafcillin/cefazolin for MSSA)

**Skin/Soft Tissue (Outpatient):**
- **Cephalexin 500mg PO QID**
- **Dicloxacillin 500mg PO QID**

**Osteomyelitis:**
- **Nafcillin 2g IV q4h** OR **cefazolin 2g IV q8h × 6 weeks**
- **Oral step-down** (after 2-4 weeks IV): Cephalexin 500mg QID

**MRSA Infections:**

**Bacteremia/Endocarditis:**
- **Vancomycin 15-20 mg/kg IV q8-12h** (target trough 15-20 mcg/mL) × 4-6 weeks
- **Alternative:** Daptomycin 8-10 mg/kg IV daily (higher dose for bacteremia/endocarditis)

**Skin/Soft Tissue:**
- **TMP-SMX DS PO BID** (outpatient)
- **Doxycycline 100mg PO BID**
- **Clindamycin 300-450mg PO TID** (if local resistance <10-15%)

**Pneumonia:**
- **Vancomycin 15-20 mg/kg IV q8-12h** + **consider linezolid 600mg IV/PO BID** (better lung penetration)

**Osteomyelitis/PJI:**
- **Vancomycin IV × 2-6 weeks**, then **oral step-down**
- **Rifampin 300-450mg PO BID** (add for biofilm infections like PJI)

**Alternative MRSA Agents:**
- **Linezolid 600mg IV/PO BID** (pneumonia, osteomyelitis - good oral bioavailability)
- **Daptomycin 6-10 mg/kg IV daily** (bacteremia, endocarditis, osteomyelitis)
- **Ceftaroline 600mg IV q12h** (MRSA with β-lactam activity)

**Toxin-Mediated Syndromes:**

**Toxic Shock Syndrome:**
- **Clindamycin 900mg IV q8h** (inhibits toxin production)
- **+ Vancomycin** OR **nafcillin** (bactericidal)
- **Remove source** (tampon, foreign body, debride wound)
- **IVIG 2 g/kg IV × 1** (if severe, refractory shock)

**SSSS:**
- **Nafcillin** OR **vancomycin** (if MRSA)
- **Supportive care** (fluid/electrolyte management, skin care)

**Food Poisoning:**
- **Supportive care only** (preformed toxin, self-limited)

### **Complicated *S. aureus* Bacteremia (SAB):**

**All SAB is High-Risk:**
- **Must evaluate for complications:**
  - **Echocardiography** (TTE, often TEE) - r/o endocarditis
  - **Search for metastatic foci** (spine MRI if back pain, joint aspiration if arthralgia)
  - **Remove infected devices** (PICC, pacemaker, prosthetic joint)

**Duration of Therapy:**
- **Uncomplicated (rare):** 14 days (low-risk criteria: no prosthetic material, negative TEE, bacteremia cleared within 2-4 days, no metastatic foci)
- **Complicated (most):** 4-6 weeks
  - Endocarditis, osteomyelitis, retained device, persistent bacteremia >3-5 days

**Do NOT Use Vancomycin for MSSA:**
- **Inferior outcomes** vs. nafcillin/cefazolin
- **Higher mortality** with vancomycin for MSSA bacteremia

### **Virulence Factors:**

**Toxins:**
- **TSST-1** (toxic shock syndrome toxin) - superantigen
- **Panton-Valentine leukocidin (PVL)** - necrotizing pneumonia, skin abscesses
- **Exfoliative toxins (ETA, ETB)** - SSSS
- **Enterotoxins** - food poisoning

**Surface Proteins:**
- **Protein A** (binds Fc region of IgG, evades opsonization)
- **Coagulase** (clots plasma, protects from phagocytosis)

**Biofilm:**
- **Prosthetic device infections** (protects from antibiotics, immune clearance)

### **Special Considerations:**

**Persistent Bacteremia:**
- **If positive blood cultures >3-5 days:**
  - Evaluate for endocarditis (TEE)
  - Search for metastatic foci (abscess, osteomyelitis)
  - Remove infected devices
  - Consider switching antibiotics (e.g., add rifampin, switch to daptomycin)

**MRSA Decolonization:**
- **Mupirocin nasal 2% BID × 5 days** (apply to nares)
- **Chlorhexidine body wash daily × 5-14 days**
- **Indications:** Recurrent MRSA infections (≥2 in 6 months)

**Vancomycin "Creep" (MIC Increase):**
- **If MSSA with vancomycin MIC ≥1.5 mcg/mL:** Switch to daptomycin (better outcomes)

## Key Points

### **MSSA: Nafcillin/Cefazolin (NOT Vancomycin):**
- **Vancomycin inferior** for MSSA (higher mortality)
- **Nafcillin 2g IV q4h** OR **cefazolin 2g IV q8h**

### **MRSA: Vancomycin (Trough 15-20):**
- **Vancomycin 15-20 mg/kg IV q8-12h**
- **Alternative:** Daptomycin 8-10 mg/kg daily (bacteremia/endocarditis)

### **All SAB = High-Risk:**
- **Echo (TTE, often TEE)**
- **Search for metastatic foci**
- **Remove devices**
- **Most need 4-6 weeks** treatment

### **Toxin Syndromes:**
- **TSS:** Clindamycin (inhibits toxin) + vancomycin/nafcillin + IVIG
- **SSSS:** Nafcillin/vancomycin
- **Food poisoning:** Supportive only (preformed toxin)

### **Necrotizing Pneumonia:**
- **PVL-positive strains** (CA-MRSA)
- **High mortality**, often post-influenza

### **Clinical Pearls:**
- **MSSA:** Nafcillin/cefazolin (NOT vancomycin - inferior outcomes)
- **MRSA:** Vancomycin (trough 15-20) OR daptomycin 8-10 mg/kg
- **All SAB:** Echo, search for foci, remove devices, usually 4-6 weeks
- **TSS:** Clindamycin (inhibits toxin) + vancomycin/nafcillin + IVIG
- **Persistent bacteremia:** TEE, search for abscess/osteomyelitis, remove devices

## Sources

- [IDSA: *S. aureus* Bacteremia Guidelines 2024]
- [CID: MRSA Management 2024]

## Media

N/A
